JPMorgan raised AbbVie target from USD 285.00 to USD 300.00 for AbbVie stock
Published on 10/13/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- JPMorgan raised its AbbVie price target from USD 285.00 to USD 300.00 on October 8, 2026.
- AbbVie reported USD 16.99 billion in second-quarter 2026 revenue, up 10.20 percent year over year.
- The Lang & Schwarz price was EUR 253.25 on October 13, 2026 at 11:52 a.m. CEST.
- AbbVie is scheduled to report third-quarter 2026 results on October 30, 2026.
AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 253.25 at Lang & Schwarz on October 13, 2026 at 11:52 a.m. CEST. Markets Insider reported that JPMorgan analyst Chris Schott raised AbbVie's price target to USD 300.00 from USD 285.00 on October 8, 2026, while keeping an Overweight rating.
AbbVie events build toward results
On July 31, 2026, AbbVie reported second-quarter revenue of USD 16.99 billion, up 10.20 percent year over year, and adjusted earnings per share of USD 3.65. Yahoo Finance published the Q2 2026 earnings call transcript, which said adjusted earnings per share exceeded the guidance midpoint by USD 0.06.
On October 8, 2026, JPMorgan lifted its target from USD 285.00 to USD 300.00. On October 13, 2026, the Lang & Schwarz quote stood at EUR 253.25, making the market price the latest dated figure in this sequence.
What supports the pipeline?
The second-quarter portfolio supplied the operating evidence behind the target revision. According to Yahoo Finance, Skyrizi sales reached USD 5.50 billion, up 24.00 percent operationally, while Rinvoq sales exceeded USD 2.50 billion, up 23.70 percent operationally. Humira sales fell 36.10 percent operationally to USD 756.00 million, showing the continuing replacement task.
Management also guided to full-year 2026 adjusted earnings per share of USD 13.87 to USD 14.07 and forecast third-quarter revenue of USD 17.20 billion. The same transcript put expected third-quarter adjusted earnings per share at USD 3.84 to USD 3.88, giving investors a defined benchmark for the October report.
October report sets the next test
Trivano reported that AbbVie will announce third-quarter 2026 financial results on October 30, 2026, before the market opens. The report will test whether Skyrizi and Rinvoq can sustain the growth rates that offset Humira erosion in the second quarter.
At Lang & Schwarz, AbbVie stock was trading at EUR 253.25 on October 13, 2026 at 11:52 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.
AbbVie stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 13, 2026, 11:52 a.m. CEST): EUR 253.25
- Market capitalization: USD 496.5 billion (as of October 12, 2026)
- 52-week range: USD 190.75-281.28 (as of October 12, 2026)
- Sector: Health Care
- Next earnings date: October 30, 2026
Market context: Market report S&P 500.
